Rhumbline Advisers Boosts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX
MarketBeat
Rhumbline Advisers grew its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 131,950 shares of the company's stock after buying an additional 7,872 shar
NASDAQ:CRNX